Clinical Trials · NCT01064687
A Study in Participants With Type 2 Diabetes Mellitus
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 978
- Start date
- Feb 2010
- Locations
- 89 sites, 4 countries
- Primary endpoint
- Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)